@ibioinc.com
iBio is pioneering the next generation of antibody therapeutics, leveraging our artificial intelligence-based and epitope steered antibody discovery platform
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
Icon
JPEG
About
Description
Through their state-of-the-art artificial intelligence-based and epitope steered antibody discovery platform, they are leading the way in developing the next generation of antibody drugs. Traditional methods of antibody development can be time-consuming and costly, often relying on chance for success. However, iBio's Discovery Platform offers a more precise and guided approach, employing an artificial intelligence engine to actively steer the discovery process.
With their patented AI-driven Epitope Engineering Engine, proprietary Antibody Library, and StableHu Antibody Optimizer, iBio is able to generate functionally enriched libraries and optimize next-gen bispecifics. By moving beyond trial-and-error methods, iBio aims to bring cancer therapeutics based on previously undruggable proteins into the clinic faster and more cost-effectively. They have a robust business model that includes strategic partnerships, proprietary pipeline development, and third-party collaborations, which allows them to grow a focused and capital-efficient business.
Overall, iBio is at the forefront of antibody therapeutics, leveraging cutting-edge technology to drive innovation and improve patient outcomes in the field of cancer treatment
Company Type
Public Company
Company Size
11-50
Year Founded
2008
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories